AP
REGN icon

Appleton Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Appleton Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-907
Closed -$797K – 283
2023
Q4 		$797K Hold
907
– – 0.06% 152
2023
Q3 		$746K Sell
907
-3
-0.3% -$2.36K 0.07% 153
2023
Q2 		$654K Hold
910
– – 0.06% 174
2023
Q1 		$748K Hold
910
– – 0.07% 175
2022
Q4 		$657K Hold
910
– – 0.06% 179
2022
Q3 		$627K Hold
910
– – 0.06% 183
2022
Q2 		$538K Sell
910
-8
-0.9% -$5.2K 0.05% 194
2022
Q1 		$641K Sell
918
-3
-0.3% -$1.9K 0.05% 190
2021
Q4 		$582K Buy
+921
New +$566K 0.04% 208

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Appleton Partners's REGN Position: Q1 2024 in Review

Appleton Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 907 shares — an estimated $797K sold.

Appleton Partners first reported a position in REGN in Q4 2021 and held it in 9 quarters. The position peaked at $797K in Q4 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Appleton Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Appleton Partners sold 907 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $797K.
  • Appleton Partners first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Appleton Partners's Regeneron Pharmaceuticals position peaked at $797K in Q4 2023.
  • 1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Appleton Partners's 13F filing for Q1 2024, filed 1 Apr 2024.